Somatic Structure Variants As a Biomarker to Predict Immune Checkpoint Inhibitor Response by Generating Anti-Tumour Antigen
Annals of internal medicine(2023)SCI 1区
University College London | The Francis Crick Institute
Abstract
The introduction of checkpoint inhibitors (CPI) has revolutionised the treatment of advanced cancers, which act to ameliorate the anti-tumour response through blocking inhibitive immune checkpoint receptors. Whole-exome sequencing (WES) based estimates of tumour mutational burden (TMB) has been robustly associated with response to CPI therapy across multiple tumour types and a threshold of ≥10 mutations per megabase (Mb) is now an FDA-approved biomarker for treatment with pembrolizumab. However, studies to date have been limited to whole exome sequencing (WES), with no data yet reported on the utility of whole genome sequencing (WGS) as a biomarker to predict CPI response. WGS data can identify non-coding alterations which impact the expression of immune regulatory genes, variants likely to form non-coding epitopes, including novel open reading frame mutations especially structure variants (SV). Here, we have identified a pan-cancer cohort of n=364 patients treated with CPI from Genomics England 100,000 Genomes Project (GEL). We find that SV burden is highly associated with worse CPI response (HR =1.3 (1.0-1.8) , p-value = 0.037) and high SV burden group have low tumour-infiltrating lymphocyte (TIL) score (P-value < 0.0001). However, we found that patients who have high proportion of SV derived neoantigen group improved overall survival (HR = 0.44 (0.27-0.73) , p-value = 0.002). In addition, enhancer region alteration of antigen present gene was observed in 43 patients (12%) and was associated with worse CPI response. (HR = 1.5 (1.0-2.2), P-value = 0.034). We further explored the SV derived neoantigen generate neoantigen-specific T cell response. Summary of Cox Model from structure variant Variables No. patients HR (95% CI) P Sex Female 164 Male 200 1.15 ( 0.87-1.52) 0.3285 Cancer Type Others 59 Lung 88 1.39 (0.91-2.14) 0.1255 Melanoma 155 0.84 (0.56-1.28) 0.4267 Renal 62 0.84 (0.52-1.38) 0.495 TMB estimated WGS 364 0.98 (0.97-0.99) 0.0036 SV burden Low 182 High 182 1.36 (1.02-1.81) 0.0358 Proportion of anti-tumour antigen from SV Low 49 High 47 0.48 (0.29-0.8) 0.0045 antigen non-generate 268 0.49 (0.35-0.7) < 0.0001 Citation Format: Hongui Cha, Benjamin Simpson, Charles Swanton, Kevin Litchfield, Genomics England Research Consortium. Somatic structure variants as a biomarker to predict immune checkpoint inhibitor response by generating anti-tumour antigen [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3137.
MoreTranslated text
Key words
Cancer Immunoediting,Biomarkers for Immunotherapy,Cancer Genomics,Immune Checkpoint Blockade,Tumor Microenvironment
求助PDF
上传PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper